Exicure to Present at BIO CEO & Investor Conference, Immuno-Oncology 360° Summit and LEERINK Partners 7th Annual Global Healthcare Conference

SKOKIE, Ill.--()--Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, today announced that Dr. David Giljohann, Chief Executive Officer of Exicure, will present a company update at the annual BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 1:45 pm EST at the New York Marriott Marquis in New York City. The company will also present at the Immuno-Oncology 360° Summit (IO360°) on Thursday, February 8, 2018 at 11:15 am EST. This meeting will take place at The Roosevelt Hotel in New York City.

Additionally, the company plans to present a company overview at the LEERINK Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018 at 9:30 am EST at the Lotte New York Palace Hotel in New York City.

A live webcast of the BIO CEO & Investor Conference and the LEERINK Partners Global Healthcare Conference presentations will be available on the Events & Presentations section of Exicure’s website and will also be archived.

About Exicure, Inc.
Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid (SNA™) architecture unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, Ill. www.exicuretx.com

Contacts

Exicure, Inc.
Karen Sharma, 781-235-3060
ksharma@macbiocom.com

Recent Stories

RSS feed for Exicure, Inc.

Release Summary

Exicure to Present at BIO CEO & Investor Conference, Immuno-Oncology 360° Summit and LEERINK Partners 7th Annual Global Healthcare Conference

Exicure, Inc.